Managersrecord · ✦ samengesteld · gearchiveerd kwartaal
Viking Global Investors
Founded by Andreas Halvorsen · Stamford, CT · CIK 1103804 · EDGAR-ingediende stukken ↗
Fundamental long/short equity.
$26.02BGerapporteerde 13F-waarde
82Posities
41.4%Top-10-gewicht
36.80Effectieve posities
n/aGeschat. omzet
+0Nieuw
−0Uitstappen
Gerapporteerde 13F-portefeuillewaarde omvat alleen Amerikaanse rapporteerbare longposities, geen contanten, obligaties, shortposities of niet-Amerikaanse posities. Het is niet het beheerd vermogen. Geen vergelijkbare eerdere indiening; kolommen voor wijzigingen niet beschikbaar dit kwartaal.
Sectorblootstelling
Technologie
25.8%
Gezondheidszorg
16.2%
Financiële dienstverlening
15.9%
Cyclische consumentengoederen
13.5%
Communicatiediensten
8.1%
Industrie
7.7%
Defensieve consumentengoederen
7.1%
Basismaterialen
2.7%
Vastgoed
2.6%
Nutsbedrijven
0.3%
Aandeel van gerapporteerde waarde van gewone aandelen; (±pp) ten opzichte van vorig kwartaal.
De portefeuille · Q2 2024
| # | Effect | Gewicht | Waarde | Aandelen | Δ aandelen | Gehouden | |
|---|---|---|---|---|---|---|---|
| 1 | AMZN Amazon.com, Inc. | 6.9% | $1.80B | 9.29M | n/a | n/c | 1 |
| 2 | ADBE Adobe Inc. | 4.9% | $1.26B | 2.28M | n/a | n/c | 1 |
| 3 | PM Philip Morris International… | 4.2% | $1.11B | 10.91M | n/a | n/c | 1 |
| 4 | MSFT Microsoft Corporation | 3.9% | $1.02B | 2.29M | n/a | n/c | 1 |
| 5 | APG APi Group Corporation | 3.9% | $1.02B | 27.03M | n/a | n/c | 1 |
| 6 | USB U.S. Bancorp | 3.9% | $1.01B | 25.40M | n/a | n/c | 1 |
| 7 | AAPL Apple Inc. | 3.7% | $966.89M | 4.59M | n/a | n/c | 1 |
| 8 | WDAY Workday, Inc. | 3.4% | $885.29M | 3.96M | n/a | n/c | 1 |
| 9 | LVS Las Vegas Sands Corp. | 3.4% | $875.52M | 19.79M | n/a | n/c | 1 |
| 10 | PGR The Progressive Corporation | 3.2% | $832.26M | 4.01M | n/a | n/c | 1 |
| 11 | FTV Fortive Corporation | 2.9% | $743.93M | 10.04M | n/a | n/c | 1 |
| 12 | ROIV Roivant Sciences Ltd. | 2.8% | $730.98M | 69.16M | n/a | n/c | 1 |
| 13 | DLTR Dollar Tree, Inc. | 2.8% | $726.98M | 6.81M | n/a | n/c | 1 |
| 14 | BBIO BridgeBio Pharma, Inc. | 2.4% | $636.31M | 25.12M | n/a | n/c | 1 |
| 15 | NFLX Netflix, Inc. | 2.4% | $629.57M | 932.87K | n/a | n/c | 1 |
| 16 | JPM JPMorgan Chase & Co. | 2.3% | $608.77M | 3.01M | n/a | n/c | 1 |
| 17 | DASH DoorDash, Inc. | 2.3% | $602.20M | 5.54M | n/a | n/c | 1 |
| 18 | BMRN BioMarin Pharmaceutical Inc. | 2.2% | $581.54M | 7.06M | n/a | n/c | 1 |
| 19 | HDB HDFC Bank Limited | 2.2% | $563.33M | 8.76M | n/a | n/c | 1 |
| 20 | MCD McDonald's Corporation | 1.8% | $478.08M | 1.88M | n/a | n/c | 1 |
| 21 | AVGO Broadcom Inc. | 1.8% | $470.58M | 293.10K | n/a | n/c | 1 |
| 22 | TMUS T-Mobile US, Inc. | 1.7% | $439.18M | 2.49M | n/a | n/c | 1 |
| 23 | GEV GE Vernova Inc. | 1.6% | $416.53M | 2.43M | n/a | n/c | 1 |
| 24 | AMP Ameriprise Financial, Inc. | 1.5% | $388.32M | 909.02K | n/a | n/c | 1 |
| 25 | CPT Camden Property Trust | 1.4% | $355.65M | 3.26M | n/a | n/c | 1 |
| 26 | GSM Ferroglobe PLC | 1.2% | $324.11M | 1.67M | n/a | n/c | 1 |
| 27 | CBRE CBRE Group, Inc. | 1.2% | $322.63M | 3.62M | n/a | n/c | 1 |
| 28 | RPRX Royalty Pharma plc | 1.2% | $315.65M | 11.97M | n/a | n/c | 1 |
| 29 | TEAM Atlassian Corporation | 1.0% | $259.30M | 1.47M | n/a | n/c | 1 |
| 30 | FCX Freeport-McMoRan Inc. | 1.0% | $254.17M | 5.23M | n/a | n/c | 1 |
| 31 | EQH Equitable Holdings, Inc. | 0.9% | $239.42M | 5.86M | n/a | n/c | 1 |
| 32 | F Ford Motor Company | 0.9% | $235.62M | 18.79M | n/a | n/c | 1 |
| 33 | UNH UnitedHealth Group… | 0.9% | $224.99M | 441.80K | n/a | n/c | 1 |
| 34 | INTU Intuit Inc. | 0.8% | $220.82M | 335.99K | n/a | n/c | 1 |
| 35 | ACHC Acadia Healthcare Company… | 0.8% | $218.61M | 3.24M | n/a | n/c | 1 |
| 36 | HCA HCA Healthcare, Inc. | 0.8% | $210.17M | 654.17K | n/a | n/c | 1 |
| 37 | DDOG Datadog, Inc. | 0.7% | $178.46M | 1.38M | n/a | n/c | 1 |
| 38 | NVDA NVIDIA Corporation | 0.7% | $171.05M | 1.38M | n/a | n/c | 1 |
| 39 | MMM 3M Company | 0.6% | $168.02M | 1.64M | n/a | n/c | 1 |
| 40 | CSX CSX Corporation | 0.6% | $158.50M | 4.74M | n/a | n/c | 1 |
| 41 | NEWAMSTERDAM PHARMA COMPANY (niet toegewezen) | n/a | $154.15M | 8.02M | n/a | n/a | |
| 42 | UBS UBS Group AG | 0.6% | $152.69M | 5.19M | n/a | n/c | 1 |
| 43 | RRX Regal Rexnord Corporation | 0.6% | $151.87M | 1.12M | n/a | n/c | 1 |
| 44 | ISRG Intuitive Surgical, Inc. | 0.6% | $150.31M | 337.89K | n/a | n/c | 1 |
| 45 | SPOT Spotify Technology S.A. | 0.6% | $149.04M | 474.98K | n/a | n/c | 1 |
| 46 | EPAM EPAM Systems, Inc. | 0.5% | $142.26M | 756.26K | n/a | n/c | 1 |
| 47 | META Meta Platforms, Inc. | 0.5% | $134.25M | 266.26K | n/a | n/c | 1 |
| 48 | CHTR Charter Communications, Inc. | 0.5% | $131.12M | 438.60K | n/a | n/c | 1 |
| 49 | LLY Eli Lilly and Company | 0.5% | $130.53M | 144.18K | n/a | n/c | 1 |
| 50 | ITGR Integer Holdings Corporation | 0.5% | $128.73M | 1.11M | n/a | n/c | 1 |
| 51 | SHW The Sherwin-Williams Company | 0.5% | $121.70M | 407.79K | n/a | n/c | 1 |
| 52 | APO Apollo Global Management… | 0.4% | $114.67M | 971.22K | n/a | n/c | 1 |
| 53 | ADPT Adaptive Biotechnologies… | 0.4% | $108.58M | 29.99M | n/a | n/c | 1 |
| 54 | CRM Salesforce, Inc. | 0.4% | $104.16M | 405.13K | n/a | n/c | 1 |
| 55 | LAB Standard BioTools Inc. | 0.4% | $103.81M | 58.65M | n/a | n/c | 1 |
| 56 | OSCR Oscar Health, Inc. | 0.4% | $93.78M | 5.93M | n/a | n/c | 1 |
| 57 | PCOR Procore Technologies, Inc. | 0.3% | $91.15M | 1.37M | n/a | n/c | 1 |
| 58 | ALL The Allstate Corporation | 0.3% | $87.04M | 545.18K | n/a | n/c | 1 |
| 59 | MCK McKesson Corporation | 0.3% | $83.03M | 142.17K | n/a | n/c | 1 |
| 60 | FIVN Five9, Inc. | 0.3% | $76.49M | 1.73M | n/a | n/c | 1 |
| 61 | NRG NRG Energy, Inc. | 0.3% | $73.46M | 943.46K | n/a | n/c | 1 |
| 62 | VKTX Viking Therapeutics, Inc. | 0.3% | $71.80M | 1.35M | n/a | n/c | 1 |
| 63 | CVNA Carvana Co. | 0.3% | $71.26M | 553.62K | n/a | n/c | 1 |
| 64 | INSM Insmed Incorporated | 0.3% | $69.41M | 1.04M | n/a | n/c | 1 |
| 65 | PHARVARIS N V (niet toegewezen) | n/a | $68.68M | 3.65M | n/a | n/a | |
| 66 | FDMT 4D MOLECULAR THERAPEUTICS IN | 0.2% | $61.60M | 2.93M | n/a | n/c | 1 |
| 67 | IMVT Immunovant, Inc. | 0.2% | $61.27M | 2.32M | n/a | n/c | 1 |
| 68 | VRT Vertiv Holdings Co | 0.2% | $59.71M | 689.69K | n/a | n/c | 1 |
| 69 | KKR KKR & Co. Inc. | 0.2% | $57.37M | 545.09K | n/a | n/c | 1 |
| 70 | DNA Ginkgo Bioworks Holdings… | 0.2% | $47.83M | 143.09M | n/a | n/c | 1 |
| 71 | LBPH LONGBOARD PHARMACEUTICALS IN | 0.2% | $44.84M | 1.66M | n/a | n/c | 1 |
| 72 | LPLA LPL Financial Holdings Inc. | 0.1% | $36.31M | 130.00K | n/a | n/c | 1 |
| 73 | ZLAB Zai Lab Limited | 0.1% | $35.31M | 2.04M | n/a | n/c | 1 |
| 74 | DAWN Day One Biopharmaceuticals… | 0.1% | $35.26M | 2.56M | n/a | n/c | 1 |
| 75 | ORIC ORIC Pharmaceuticals, Inc. | 0.1% | $28.28M | 4.00M | n/a | n/c | 1 |
| 76 | RBRK Rubrik, Inc. | 0.1% | $27.51M | 897.17K | n/a | n/c | 1 |
| 77 | EWTX Edgewise Therapeutics, Inc. | 0.1% | $26.68M | 1.48M | n/a | n/c | 1 |
| 78 | INBX Inhibrx Biosciences Inc. | 0.1% | $25.33M | 1.79M | n/a | n/c | 1 |
| 79 | PEPG PEPGEN INC | 0.1% | $23.66M | 1.48M | n/a | n/c | 1 |
| 80 | SNY Sanofi | 0.1% | $15.83M | 326.29K | n/a | n/c | 1 |
| 81 | TRVI Trevi Therapeutics, Inc. | 0.1% | $13.11M | 4.40M | n/a | n/c | 1 |
| 82 | RLYB RALLYBIO CORP | 0.0% | $5.62M | 4.19M | n/a | n/c | 1 |
Uitsluitend gewone aandelen (SH)-posities; optieregels staan op het tabblad Opties en worden nooit gesaldeerd. ✂ = wijziging berekend ten opzichte van splitsingsangepaste eerdere aandelen. "Aangehouden N+" = elke kwartaal aangehouden in ons venster, mogelijk langer.
| Effect | Aandelen | Vorig | Wijziging | Waarde | Gewicht | Reeks |
|---|---|---|---|---|---|---|
| Geen dit kwartaal. | ||||||
| Effect | Aandelen | Vorig | Wijziging | Waarde | Gewicht | Reeks |
|---|---|---|---|---|---|---|
| Geen dit kwartaal. | ||||||
| Effect | Aandelen | Vorig | Wijziging | Waarde | Gewicht | Reeks |
|---|---|---|---|---|---|---|
| Geen dit kwartaal. | ||||||
| Effect | Aandelen | Vorig | Wijziging | Waarde | Gewicht | Reeks |
|---|---|---|---|---|---|---|
| Geen dit kwartaal. | ||||||
Leeftijd van de positie
800–1 kwartalen
Opeenvolgende kwartalen dat elke huidige positie is gerapporteerd, binnen ons datavenster.
Vergelijkbare managers
| Manager | Gemeenschappelijke posities | Naamoverlap | Gewogen gelijkenis | |
|---|---|---|---|---|
| Soroban Capital Partners LP | 5 | 4.8% | 0.363 | Vergelijken ⇄ |
| Brown Advisory Inc | 54 | 3.7% | 0.3537 | Vergelijken ⇄ |
| Sanders Capital, LLC | 8 | 6.3% | 0.3376 | Vergelijken ⇄ |
| ValueAct Capital | 3 | 3.0% | 0.3246 | Vergelijken ⇄ |
| Dodge & Cox | 24 | 8.4% | 0.3198 | Vergelijken ⇄ |
| Clearbridge Investments, LLC | 46 | 6.3% | 0.3112 | Vergelijken ⇄ |
| Tiger Global Management | 10 | 8.1% | 0.3083 | Vergelijken ⇄ |
| Ninety One UK Ltd | 25 | 7.5% | 0.298 | Vergelijken ⇄ |
Gelijkenis van alleen gerapporteerde longposities; hedges en niet-13F-activa zijn onzichtbaar. Methodologie
Indieningsrecord
Aug 14 2026
13F-HR · periode Q2 2026
$35.08B · 90 genoteerde posities · Originele SEC-indiening bekijken ↗
May 15 2026
13F-HR · periode Q1 2026
$35.75B · 77 genoteerde posities · Originele SEC-indiening bekijken ↗
Feb 17 2026
13F-HR · periode Q4 2025
$37.68B · 76 genoteerde posities · Originele SEC-indiening bekijken ↗
Nov 14 2025
13F-HR · periode Q3 2025
$38.50B · 78 genoteerde posities · Originele SEC-indiening bekijken ↗
Aug 14 2025
13F-HR · periode Q2 2025
$34.59B · 83 genoteerde posities · Originele SEC-indiening bekijken ↗
May 15 2025
13F-HR · periode Q1 2025
$31.48B · 91 genoteerde posities · Originele SEC-indiening bekijken ↗
Feb 14 2025
13F-HR · periode Q4 2024
$30.90B · 86 genoteerde posities · Originele SEC-indiening bekijken ↗
Nov 14 2024
13F-HR · periode Q3 2024
$27.44B · 83 genoteerde posities · Originele SEC-indiening bekijken ↗
Aug 14 2024
13F-HR · periode Q2 2024
$26.02B · 82 genoteerde posities · Originele SEC-indiening bekijken ↗
Herkomst: Alle holdings geparseerd uit de 13F-informatietabellen van deze manager op SEC EDGAR; waarden zoals gerapporteerd, in hele USD. Wijzigingen vergelijken de laatste geaccepteerde versie van elk kwartaal (amendementen verwerkt) op basis van voor splitsingen gecorrigeerde aandelenaantallen.
Rapportageperiode: Q2 2024 · laatste indiening Aug 14, 2026 ·
Berekeningsmethodologie